The FDA is scheduled to hold its first public hearing today concerning the CBD industry. Ned Sharpless, a Food and Drug Administration Commissioner, commented on the meeting, stating
“There are real risks associated with [THC and CBD] and critical questions remain about the safety of their widespread use in foods and dietary supplements, as well as other consumer products — including cosmetics, which are subject to a separate regulatory framework.”
He added that the FDA is aware of the budding interest in the industry, but that the FDA is still working to evaluate how the pieces fit together, stating
“And given the new interest in marketing cannabis products across the range of areas FDA regulates, we will need to carefully evaluate how all these pieces fit together in terms of how consumers might access cannabis products,” Sharpless said.
“Nowhere is this truer than with CBD. While we have seen an explosion of interest in products containing CBD, there is still much that we don’t know.”
The meeting comes in at a time where companies are asking for an easing of cannabis rules. According to a New York Times article, many companies “will try to convince the F.D.A.” to let them sell their products in stores and online legally. At this point, the FDA has not decided anything, so the hope is that this meeting with provide some insight on the direction the FDA is leaning toward when it comes to defining standards for CBD.